Expression of y-glutamylcysteine synthetase (y-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs
1998

Gene Expression and Platinum Drug Resistance in Lung Cancer

Sample size: 76 publication Evidence: moderate

Author Information

Author(s): T Oguri, Y Fujiwara, T Isobel, O Katoh, H Watanabe, M Yamakido

Primary Institution: Hiroshima University School of Medicine

Hypothesis

The study investigates the correlation between gene expression levels of y-GCS and MRP with platinum drug exposure in lung cancer patients.

Conclusion

The study found that y-GCS and MRP expression levels were significantly higher in lung cancer tissues exposed to platinum drugs compared to non-exposed tissues.

Supporting Evidence

  • y-GCSh expression levels were significantly higher in exposed samples than in non-exposed samples.
  • MRP expression levels were elevated in tumours associated with platinum drug exposure.
  • cMOAT expression levels did not correlate with platinum drug exposure.

Takeaway

This study shows that certain genes in lung cancer can change when patients are treated with platinum drugs, which might help explain why some cancers resist treatment.

Methodology

The study analyzed 76 autopsy samples from lung cancer patients using quantitative reverse transcription polymerase chain reaction (RT-PCR) to measure mRNA levels.

Limitations

The study used autopsy samples, which may have limitations in terms of the timing of sample collection and the potential impact of post-mortem changes on gene expression.

Participant Demographics

The study included 38 patients, predominantly male (30 men, 8 women), aged 44 to 86 years, with a majority being smokers.

Statistical Information

P-Value

0.0008

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication